<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39199353</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>The Significance of Endothelial Dysfunction in Long COVID-19 for the Possible Future Pandemic of Chronic Kidney Disease and Cardiovascular Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">965</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14080965</ELocationID><Abstract><AbstractText>Various symptoms have been reported to persist beyond the acute phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which is referred to as long coronavirus disease 19 (long COVID-19). Over 65&#x2009;million individuals suffer from long COVID-19. However, the causes of long COVID-19 are largely unknown. Since long COVID-19 symptoms are observed throughout the body, vascular endothelial dysfunction is a strong candidate explaining the induction of long COVID-19. The angiotensin-converting enzyme 2 (ACE2), the entry receptor for SARS-CoV-2, is ubiquitously expressed in endothelial cells. We previously found that the risk factors for atherosclerotic cardiovascular disease (ASCVD) and a history of ASCVD raise the risk of severe COVID-19, suggesting a contribution of pre-existing endothelial dysfunction to severe COVID-19. Here, we show a significant association of endothelial dysfunction with the development of long COVID-19 and show that biomarkers for endothelial dysfunction in patients with long COVID-19 are also crucial players in the development of ASCVD. We consider the influence of long COVID-19 on the development of chronic kidney disease (CKD) and ASCVD. Future assessments of the outcomes of long COVID-19 in patients resulting from therapeutic interventions that improve endothelial function may imply the significance of endothelial dysfunction in the development of long COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Hidekatsu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4199-3665</Identifier><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adachi</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakoshima</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuyama</LastName><ForeName>Hisayuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2871-8340</Identifier><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sako</LastName><ForeName>Akahito</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General Medicine, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="Y">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atherosclerotic cardiovascular disease</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">long coronavirus disease 19</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest in relation to the present review paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39199353</ArticleId><ArticleId IdType="pmc">PMC11352301</ArticleId><ArticleId IdType="doi">10.3390/biom14080965</ArticleId><ArticleId IdType="pii">biom14080965</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet T. Facing up to long COVID. Lancet. 2020;396:1861. doi: 10.1016/S0140-6736(20)32662-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32662-3</ArticleId><ArticleId IdType="pmc">PMC7834723</ArticleId><ArticleId IdType="pubmed">33308453</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadman M., Couzin-Frankel J., Kaiser J., Matacic C. A rampage through the body. Science. 2020;368:356&#x2013;360. doi: 10.1126/science.368.6489.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.368.6489.356</ArticleId><ArticleId IdType="pubmed">32327580</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Morrone M.C., Patrono C., Santoro M.G., Schiaffino S., Remuzzi G., Bussolati G. Long Covid: Where we stand and challenges ahead. Cell Death Differ. 2022;29:1891&#x2013;1900. doi: 10.1038/s41418-022-01052-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-01052-6</ArticleId><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D., Wirtheim E., Vetter P., Kalil A.C., Bruchfeld J., Runold M., Guaraldi G., Mussini C., Gudiol C., Pujol M., et al. Long-term consequences of COVID-19: Research needs. Lancet Infect. Dis. 2020;20:1115&#x2013;1117. doi: 10.1016/S1473-3099(20)30701-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30701-5</ArticleId><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: What do we know about &#x201c;long covid&#x201d;? BMJ. 2020;370:m2815. doi: 10.1136/bmj.m2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S., Cui H., Wang T., Shen X., Ma C. Pain: A potential new label of COVID-19. Brain Behav. Immun. 2020;87:159&#x2013;160. doi: 10.1016/j.bbi.2020.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.025</ArticleId><ArticleId IdType="pmc">PMC7204693</ArticleId><ArticleId IdType="pubmed">32389704</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshijima H., Mihara T., Seki H., Hyuga S., Kuratani N., Shiga T. Incidence of long-term post-acute sequelae of SARS-CoV-2 infection related to pain and other symptoms: A systematic review and meta-analysis. PLoS ONE. 2023;18:e0250909. doi: 10.1371/journal.pone.0250909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0250909</ArticleId><ArticleId IdType="pmc">PMC10686440</ArticleId><ArticleId IdType="pubmed">38019841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H. A Significance of High Prevalence of Diabetes and Hypertension in Severe COVID-19 Patients. J. Clin. Med. Res. 2020;12:389&#x2013;392. doi: 10.14740/jocmr4218.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4218</ArticleId><ArticleId IdType="pmc">PMC7295548</ArticleId><ArticleId IdType="pubmed">32587655</ArticleId></ArticleIdList></Reference><Reference><Citation>Busetto L., Bettini S., Fabris R., Serra R., Pra C.D., Maffei P., Rossato M., Fioretto P., Vettor R. Obesity and COVID-19: An Italian Snapshot. Obesity. 2020;28:1600&#x2013;1605. doi: 10.1002/oby.22918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22918</ArticleId><ArticleId IdType="pmc">PMC7283686</ArticleId><ArticleId IdType="pubmed">32463545</ArticleId></ArticleIdList></Reference><Reference><Citation>Higham A., Singh D. Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. Obesity. 2020;28:1586&#x2013;1589. doi: 10.1002/oby.22907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22907</ArticleId><ArticleId IdType="pmc">PMC7276828</ArticleId><ArticleId IdType="pubmed">32428380</ArticleId></ArticleIdList></Reference><Reference><Citation>Yudkin J.S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care. 1999;22((Suppl. S3)):C25&#x2013;C30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10189559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H., Adachi H., Hakoshima M., Katsuyama H. Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients. Metabolites. 2023;13:736. doi: 10.3390/metabo13060736.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo13060736</ArticleId><ArticleId IdType="pmc">PMC10303074</ArticleId><ArticleId IdType="pubmed">37367894</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarafidis P.A., Bakris G.L. Review: Insulin and endothelin: An interplay contributing to hypertension development? J. Clin. Endocrinol. Metab. 2007;92:379&#x2013;385. doi: 10.1210/jc.2006-1819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2006-1819</ArticleId><ArticleId IdType="pubmed">17118997</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H. Adiposity is the Crucial Enhancer of COVID-19. Cardiol. Res. 2020;11:353&#x2013;354. doi: 10.14740/cr1118.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1118</ArticleId><ArticleId IdType="pmc">PMC7430889</ArticleId><ArticleId IdType="pubmed">32849972</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M., Bottino N., Tagliabue P., Grasselli G., Novembrino C., Chantarangkul V., Pesenti A., Peyvandi F., Tripodi A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 2020;18:1738&#x2013;1742. doi: 10.1111/jth.14850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14850</ArticleId><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H. Metabolic Syndrome and COVID-19. Cardiol. Res. 2020;11:360&#x2013;365. doi: 10.14740/cr1181.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1181</ArticleId><ArticleId IdType="pmc">PMC7666594</ArticleId><ArticleId IdType="pubmed">33224380</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutchia J., Pokharel P., Kerri A., McGaw K., Uchai S., Nji M., Goodman M. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS ONE. 2020;15:e0239802. doi: 10.1371/journal.pone.0239802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0239802</ArticleId><ArticleId IdType="pmc">PMC7529271</ArticleId><ArticleId IdType="pubmed">33002041</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieva E., Ananiev J., Yovchev Y., Arabadzhiev G., Abrashev H., Abrasheva D., Atanasov V., Kostandieva R., Mitev M., Petkova-Parlapanska K., et al. COVID-19 Complications: Oxidative Stress, Inflammation, and Mitochondrial and Endothelial Dysfunction. Int. J. Mol. Sci. 2023;24:14876. doi: 10.3390/ijms241914876.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241914876</ArticleId><ArticleId IdType="pmc">PMC10573237</ArticleId><ArticleId IdType="pubmed">37834324</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., Ibn Hadj Amor H., Jdidi J., Torjmen S., Kraiem S., Hammami R., Bahloul A., Kallel N., Moussa N., Touil I., et al. Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study. Front. Cardiovasc. Med. 2021;8:745758. doi: 10.3389/fcvm.2021.745758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.745758</ArticleId><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou E., Souvaliotis N., Lampsas S., Siasos G., Poulakou G., Theofilis P., Papaioannou T.G., Haidich A.B., Tsaousi G., Ntousopoulos V., et al. Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study. Vasc. Pharmacol. 2022;144:106975. doi: 10.1016/j.vph.2022.106975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2022.106975</ArticleId><ArticleId IdType="pmc">PMC8893931</ArticleId><ArticleId IdType="pubmed">35248780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolai L., Kaiser R., Stark K. Thromboinflammation in long COVID-the elusive key to postinfection sequelae? J. Thromb. Haemost. 2023;21:2020&#x2013;2031. doi: 10.1016/j.jtha.2023.04.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.04.039</ArticleId><ArticleId IdType="pmc">PMC10174338</ArticleId><ArticleId IdType="pubmed">37178769</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., Englert H., Byrne M., Bergin C., O&#x2019;Sullivan J.M., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19:2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Ciaula A., Liberale L., Portincasa P., Khalil M., Galerati I., Farella I., Noto A., JohnBritto S., Moriero M., Michelauz C., et al. Neutrophil degranulation, endothelial and metabolic dysfunction in unvaccinated long COVID patients. Eur. J. Clin. Investig. 2024;54:e14155. doi: 10.1111/eci.14155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.14155</ArticleId><ArticleId IdType="pubmed">38226472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Sanduzzi Zamparelli S., Mosella M., Formisano R., Molino A., Spedicato G.A., Papa A., Motta A., Di Minno M.N.D., Maniscalco M. Clinical assessment of endothelial function in convalescent COVID-19 patients: A meta-analysis with meta-regressions. Ann. Med. 2022;54:3234&#x2013;3249. doi: 10.1080/07853890.2022.2136403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2136403</ArticleId><ArticleId IdType="pmc">PMC9673781</ArticleId><ArticleId IdType="pubmed">36382632</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins-Gon&#xe7;alves R., Hottz E.D., Bozza P.T. Acute to post-acute COVID-19 thromboinflammation persistence: Mechanisms and potential consequences. Curr. Res. Immunol. 2023;4:100058. doi: 10.1016/j.crimmu.2023.100058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crimmu.2023.100058</ArticleId><ArticleId IdType="pmc">PMC10083200</ArticleId><ArticleId IdType="pubmed">37064788</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn J.Y., Zhang Y., Wu Y., Cannesson M., Cai H. Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells. Redox. Biol. 2021;46:102099. doi: 10.1016/j.redox.2021.102099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2021.102099</ArticleId><ArticleId IdType="pmc">PMC8372492</ArticleId><ArticleId IdType="pubmed">34509916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J.X., Agbana Y.L., Sun Z.S., Fei S.W., Zhao H.Q., Zhou X.N., Chen J.H., Kassegne K. Increased interleukin-6 is associated with long COVID-19: A systematic review and meta-analysis. Infect. Dis. Poverty. 2023;12:43. doi: 10.1186/s40249-023-01086-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-023-01086-z</ArticleId><ArticleId IdType="pmc">PMC10123579</ArticleId><ArticleId IdType="pubmed">37095536</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfadda A.A., Rafiullah M., Alkhowaiter M., Alotaibi N., Alzahrani M., Binkhamis K., Siddiqui K., Youssef A., Altalhi H., Almaghlouth I., et al. Clinical and biochemical characteristics of people experiencing post-coronavirus disease 2019-related symptoms: A prospective follow-up investigation. Front. Med. 2022;9:1067082. doi: 10.3389/fmed.2022.1067082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1067082</ArticleId><ArticleId IdType="pmc">PMC9763306</ArticleId><ArticleId IdType="pubmed">36561720</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Griendlingm K.K., Harrison D.G. The vascular NAD (P) H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 2003;24:471&#x2013;478. doi: 10.1016/S0165-6147(03)00233-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-6147(03)00233-5</ArticleId><ArticleId IdType="pubmed">12967772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Li X.L., Zhao C.R., Pan C.L., Zhang Z. Interleukin-6 as a Predictor of the Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Epidemiological Studies. Immunol. Investig. 2018;47:689&#x2013;699. doi: 10.1080/08820139.2018.1480034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2018.1480034</ArticleId><ArticleId IdType="pubmed">29873573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Kakkar V., Lu X. Impact of MCP-1 in atherosclerosis. Curr. Pharm. Des. 2014;20:4580&#x2013;4588. doi: 10.2174/1381612820666140522115801.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612820666140522115801</ArticleId><ArticleId IdType="pubmed">24862889</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis M.K., Gill D., Rannikm&#xe4;e K., Traylor M., Anderson C.D., Lee J.M., Kamatani Y., Hopewell J.C., Worrall B.B., Bernhagen J., et al. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. Impact of MCP-1 in atherosclerosis. Circulation. 2019;139:256&#x2013;268. doi: 10.1161/CIRCULATIONAHA.118.035905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035905</ArticleId><ArticleId IdType="pmc">PMC7477819</ArticleId><ArticleId IdType="pubmed">30586705</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward S.E., Curley G.F., Lavin M., Fogarty H., Karampini E., McEvoy N.L., Clarke J., Boylan M., Alalqam R., Worrall A.P., et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): Evidence of acute and sustained endothelial cell activation. Br. J. Haematol. 2021;192:714&#x2013;719. doi: 10.1111/bjh.17273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17273</ArticleId><ArticleId IdType="pubmed">33326604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibowo A., Pranata R., Lim M.A., Akbara M.R., Martha J.W. Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: A systematic review and meta-analysis. Int. J. Infect. Dis. 2022;117:267&#x2013;273. doi: 10.1016/j.ijid.2021.06.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.06.051</ArticleId><ArticleId IdType="pmc">PMC8236128</ArticleId><ArticleId IdType="pubmed">34192577</ArticleId></ArticleIdList></Reference><Reference><Citation>Terraube V., O&#x2019;Donnell J.S., Jenkins P.V. Factor VIII and von Willebrand factor interaction: Biological, clinical and therapeutic importance. Haemophilia. 2010;16:3&#x2013;13. doi: 10.1111/j.1365-2516.2009.02005.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2516.2009.02005.x</ArticleId><ArticleId IdType="pubmed">19473409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X.L. ADAMTS13 and von willebrand factor in thrombotic thrombocytopenic purpura. Annu. Rev. Med. 2015;66:211&#x2013;225. doi: 10.1146/annurev-med-061813-013241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-061813-013241</ArticleId><ArticleId IdType="pmc">PMC4599565</ArticleId><ArticleId IdType="pubmed">25587650</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N., Heightman M., Hillman T., Wall E., Bell R., Kessler A., Neave L., Doyle A., Devaraj A., Singh D., et al. Impaired exercise capacity in post-COVID-19 syndrome: The role of VWF-ADAMTS13 axis. Blood. Adv. 2022;6:4041&#x2013;4048. doi: 10.1182/bloodadvances.2021006944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I., Baronciani L., Artoni A., Colpani P., Biganzoli M., Cozzi G., Novembrino C., Boscolo Anzoletti M., De Zan V., Pagliari M.T., et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J. Thromb. Haemost. 2021;19:513&#x2013;521. doi: 10.1111/jth.15191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15191</ArticleId><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Feng Y., Jia Y., Zhang X., Li L., Bai X., Jiao L. Prognostic value of von willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis. Thromb. Res. 2022;218:83&#x2013;98. doi: 10.1016/j.thromres.2022.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.08.017</ArticleId><ArticleId IdType="pmc">PMC9385270</ArticleId><ArticleId IdType="pubmed">36027630</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Z.W., van Wijk Xander M.R., Pham H.P., Marin M.J. Role of von willebrand factor in COVID-19 associated coagulopathy. J. Appl. Lab. Med. 2021;6:1305&#x2013;1315. doi: 10.1093/jalm/jfab042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jalm/jfab042</ArticleId><ArticleId IdType="pmc">PMC8135722</ArticleId><ArticleId IdType="pubmed">33930144</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X., Wang X., Fan M., Zhao J., Lin L., Liu J. Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta-analysis. Diabetes Metab. Res. Rev. 2020;36:e3193. doi: 10.1002/dmrr.3193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3193</ArticleId><ArticleId IdType="pubmed">31145835</ArticleId></ArticleIdList></Reference><Reference><Citation>Whincup P.H., Danesh J., Walker M., Lennon L., Thomson A., Appleby P., Rumley A., Lowe G.D. von Willebrand factor and coronary heart disease: Prospective study and meta-analysis. Eur. Heart. J. 2002;23:1764&#x2013;1770. doi: 10.1053/euhj.2001.3237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/euhj.2001.3237</ArticleId><ArticleId IdType="pubmed">12419296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabater-Lleal M., Huffman J.E., de Vries P.S., Marten J., Mastrangelo M.A., Song C., Pankratz N., Ward-Caviness C.K., Yanek L.R., Trompet S., et al. Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. Circulation. 2019;139:620&#x2013;635. doi: 10.1161/CIRCULATIONAHA.118.034532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.034532</ArticleId><ArticleId IdType="pmc">PMC6438386</ArticleId><ArticleId IdType="pubmed">30586737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonneveld M.A., de Maat M.P., Leebeek F.W. von Willebrand factor and ADAMTS13 in arterial thrombosis: A systematic review and meta-analysis. Blood. Rev. 2014;28:167&#x2013;178. doi: 10.1016/j.blre.2014.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2014.04.003</ArticleId><ArticleId IdType="pubmed">24825749</ArticleId></ArticleIdList></Reference><Reference><Citation>Maino A., Siegerink B., Lotta L.A., Crawley J.T., le Cessie S., Leebeek F.W., Lane D.A., Lowe G.D., Peyvandi F., Rosendaal F.R. Plasma ADAMTS-13 levels and the risk of myocardial infarction: An individual patient data meta-analysis. J. Thromb. Haemost. 2015;13:1396&#x2013;1404. doi: 10.1111/jth.13032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13032</ArticleId><ArticleId IdType="pubmed">26073931</ArticleId></ArticleIdList></Reference><Reference><Citation>Medcalf R.L., Keragala C.B. The fibrinolytic system: Mysteries and opportunities. Hemasphere. 2021;5:e570. doi: 10.1097/HS9.0000000000000570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000570</ArticleId><ArticleId IdType="pmc">PMC8171360</ArticleId><ArticleId IdType="pubmed">34095754</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer K., Zieger B. Endothelial cells and coagulation. Cell Tissue Res. 2022;387:391&#x2013;398. doi: 10.1007/s00441-021-03471-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-021-03471-2</ArticleId><ArticleId IdType="pmc">PMC8975780</ArticleId><ArticleId IdType="pubmed">34014399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Warnock M., Harbaugh A., Yalavarthi S., Gockman K., Zuo M., Madison J.A., Knight J.S., Kanthi Y., Lawrence D.A. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci. Rep. 2021;11:1580. doi: 10.1038/s41598-020-80010-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80010-z</ArticleId><ArticleId IdType="pmc">PMC7810990</ArticleId><ArticleId IdType="pubmed">33452298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nougier C., Benoit R., Simon M., Desmurs-Clavel H., Marcotte G., Argaud L., David J.S., Bonnet A., Negrier C., Dargaud Y. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-CoV2 associated thrombosis. J. Thromb. Haemost. 2020;18:2215&#x2013;2219. doi: 10.1111/jth.15016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15016</ArticleId><ArticleId IdType="pmc">PMC7405476</ArticleId><ArticleId IdType="pubmed">32668058</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Garcia D., Miltiades A., Yim P., Parsons S., Elisman K., Mansouri M.T., Wagener G., Harrison N.L. Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. Int. J. Hematol. 2022;116:937&#x2013;946. doi: 10.1007/s12185-022-03437-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-022-03437-2</ArticleId><ArticleId IdType="pmc">PMC9395834</ArticleId><ArticleId IdType="pubmed">35994163</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki E., Barion B.G., da Rocha T.R.F., Di Giacomo G., Ho Y.L., Rothschild C., Fatobene G., de Carvalho Moraes B.D.G., Stefanello B., Villa&#xe7;a P.R., et al. Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity. J. Thromb. Thrombolysis. 2024;57:721&#x2013;729. doi: 10.1007/s11239-024-02961-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-024-02961-8</ArticleId><ArticleId IdType="pubmed">38523179</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari M., Jarahzadeh M.H., Dastgheib S.A., Seifi-Shalamzari N., Raee-Ezzabadi A., Sadeghizadeh-Yazdi J., Akbarian E., Neamatzadeh H. Association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke: A Huge Meta-Analysis based on 44 Studies. Acta. Medica. 2020;63:31&#x2013;42. doi: 10.14712/18059694.2020.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.14712/18059694.2020.13</ArticleId><ArticleId IdType="pubmed">32422114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulos G.K., Bagos P.G., Tsangaris I., Tsiara C.G., Kopterides P., Vaiopoulos A., Kapsimali V., Bonovas S., Tsantes A.E. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: A Mendelian randomization meta-analysis. Clin. Chem. Lab. Med. 2014;52:937&#x2013;950. doi: 10.1515/cclm-2013-1124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2013-1124</ArticleId><ArticleId IdType="pubmed">24695040</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.Y. Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: A meta-analysis. PLoS ONE. 2012;7:e33511. doi: 10.1371/journal.pone.0033511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033511</ArticleId><ArticleId IdType="pmc">PMC3319560</ArticleId><ArticleId IdType="pubmed">22496752</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung R.G., Motazedian P., Ramirez F.D., Simard T., Di Santo P., Visintini S., Faraz M.A., Labinaz A., Jung Y., Hibbert B. Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis. Thromb. J. 2018;16:12. doi: 10.1186/s12959-018-0166-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-018-0166-4</ArticleId><ArticleId IdType="pmc">PMC5987541</ArticleId><ArticleId IdType="pubmed">29991926</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532&#x2013;1535. doi: 10.1126/science.1092385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092385</ArticleId><ArticleId IdType="pubmed">15001782</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban C.F., Ermert D., Schmid M., Abu-Abed U., Goosmann C., Nacken W., Brinkmann V., Jungblut P.R., Zychlinsky A. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009;5:e1000639. doi: 10.1371/journal.ppat.1000639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000639</ArticleId><ArticleId IdType="pmc">PMC2763347</ArticleId><ArticleId IdType="pubmed">19876394</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras F.P., Pontelli M.C., Silva C.M., Toller-Kawahisa J.E., de Lima M., Nascimento D.C., Schneider A.H., Caetit&#xe9; D., Tavares L.A., Paiva I.M., et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 2020;217:e20201129. doi: 10.1084/jem.20201129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201129</ArticleId><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe R., Matsuyama S., Shirato K., Maejima M., Fukushi S., Morikawa S., Taguchi F. Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein. J. Virol. 2008;82:11985&#x2013;11991. doi: 10.1128/JVI.01412-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01412-08</ArticleId><ArticleId IdType="pmc">PMC2583654</ArticleId><ArticleId IdType="pubmed">18786990</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J.M., Da&#xdf;ler-Plenker J., Guerci P., Huynh C., Knight J.S., et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020;217:e20200652. doi: 10.1084/jem.20200652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton E.A., He X.Y., Denorme F., Campbell R.A., Ng D., Salvatore S.P., Mostyka M., Baxter-Stoltzfus A., Borczuk A.C., Loda M., et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169&#x2013;1179. doi: 10.1182/blood.2020007008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros P., Mitsios A., Chrysanthopoulou A., Mastellos D.C., Metallidis S., Rafailidis P., Ntinopoulou M., Sertaridou E., Tsironidou V., Tsigalou C., et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Investig. 2020;130:6151&#x2013;6157. doi: 10.1172/JCI141374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141374</ArticleId><ArticleId IdType="pmc">PMC7598040</ArticleId><ArticleId IdType="pubmed">32759504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramitasuri T.I., Laksmidewi A.A.A.P., Putra I.B.K., Dalimartha F.A. Neutrophil Extracellular Traps in Coronavirus Disease-19-Associated Ischemic Stroke: A Novel Avenue in Neuroscience. Exp. Neurobiol. 2021;30:1&#x2013;12. doi: 10.5607/en20048.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en20048</ArticleId><ArticleId IdType="pmc">PMC7926042</ArticleId><ArticleId IdType="pubmed">33632982</ArticleId></ArticleIdList></Reference><Reference><Citation>Krinsky N., Sizikov S., Nissim S., Dror A., Sas A., Prinz H., Pri-Or E., Perek S., Raz-Pasteur A., Lejbkowicz I., et al. NETosis induction reflects COVID-19 severity and long COVID: Insights from a 2-center patient cohort study in Israel. J. Thromb. Haemost. 2023;21:2569&#x2013;2584. doi: 10.1016/j.jtha.2023.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.02.033</ArticleId><ArticleId IdType="pmc">PMC10088279</ArticleId><ArticleId IdType="pubmed">37054916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafqat A., Omer M.H., Albalkhi I., Alabdul Razzak G., Abdulkader H., Abdul Rab S., Sabbah B.N., Alkattan K., Yaqinuddin A. Neutrophil extracellular traps and long COVID. Front. Immunol. 2023;14:1254310. doi: 10.3389/fimmu.2023.1254310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1254310</ArticleId><ArticleId IdType="pmc">PMC10565006</ArticleId><ArticleId IdType="pubmed">37828990</ArticleId></ArticleIdList></Reference><Reference><Citation>Megens R.T., Vijayan S., Lievens D., Doring Y., van Zandvoort M.A., Grommes J., Weber C., Soehnlein O. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb. Haemost. 2012;107:597&#x2013;598. doi: 10.1160/TH11-09-0650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH11-09-0650</ArticleId><ArticleId IdType="pubmed">22318427</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., Luo W., O&#x2019;Dell A.A., Yalavarthi S., Zhao W., Subramanian V., Guo C., Grenn R.C., Thompson P.R., Eitzman D.T., et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ. Res. 2014;114:947&#x2013;956. doi: 10.1161/CIRCRESAHA.114.303312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.303312</ArticleId><ArticleId IdType="pmc">PMC4185401</ArticleId><ArticleId IdType="pubmed">24425713</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O., Zernecke A., Eriksson E.E., Rothfuchs A.G., Pham C.T., Herwald H., Bidzhekov K., Rottenberg M.E., Weber C., Lindbom L. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008;112:1461&#x2013;1471. doi: 10.1182/blood-2008-02-139634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-02-139634</ArticleId><ArticleId IdType="pmc">PMC3400540</ArticleId><ArticleId IdType="pubmed">18490516</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangeten C., Zouaoui Boudjeltia K., Delporte C., Van Antwerpen P., Korpak K. Unexpected Role of MPO-Oxidized LDLs in Atherosclerosis: In between Inflammation and Its Resolution. Antioxidants. 2022;11:874. doi: 10.3390/antiox11050874.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11050874</ArticleId><ArticleId IdType="pmc">PMC9137493</ArticleId><ArticleId IdType="pubmed">35624738</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Larragoiti N., Cano-Mendez A., Jimenez-Vega Y., Trujillo M., Guzman-Cancino P., Ambriz-Murillo Y., Viveros-Sandoval M.E. Inflammatory and Prothrombotic Biomarkers Contribute to the Persistence of Sequelae in Recovered COVID-19 Patients. Int. J. Mol. Sci. 2023;24:17468. doi: 10.3390/ijms242417468.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242417468</ArticleId><ArticleId IdType="pmc">PMC10744310</ArticleId><ArticleId IdType="pubmed">38139298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu L., Chen A., Delahunty M.D., Moore K.L., Watson S.R., McEver R.P., Tedder T.F. L-selectin binds to P-selectin glycoprotein ligand-1 on leukocytes: Interactions between the lectin, epidermal growth factor, and consensus repeat domains of the selectins determine ligand binding specificity. J. Immunol. 1996;157:3995&#x2013;4004. doi: 10.4049/jimmunol.157.9.3995.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.157.9.3995</ArticleId><ArticleId IdType="pubmed">8892633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding G., Wang J., Liu K., Huang B., Deng W., He T. Association of E-Selectin gene rs5361 polymorphism with ischemic stroke susceptibility: A systematic review and Meta-analysis. Int. J. Neurosci. 2021;131:511&#x2013;517. doi: 10.1080/00207454.2020.1750385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2020.1750385</ArticleId><ArticleId IdType="pubmed">32241219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Lou Y., Lu L., Liu Y., Chen Q., Chen X., Jin W. Heterogeneous effect of two selectin gene polymorphisms on coronary artery disease risk: A meta-analysis. PLoS ONE. 2014;9:e88152. doi: 10.1371/journal.pone.0088152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0088152</ArticleId><ArticleId IdType="pmc">PMC3912165</ArticleId><ArticleId IdType="pubmed">24498435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang J., Du X., Song M., Jia C., Liu H. Association of A561C and G98T polymorphisms in E-selectin gene with coronary artery disease: A meta-analysis. PLoS ONE. 2013;8:e79301. doi: 10.1371/journal.pone.0079301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079301</ArticleId><ArticleId IdType="pmc">PMC3832468</ArticleId><ArticleId IdType="pubmed">24260191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai H., Yang M., Sun M., Pan B., Wang Q., Wang J., Tian J., Ding G., Yang K., Song X., et al. Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis. Metabolism. 2022;137:155330. doi: 10.1016/j.metabol.2022.155330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2022.155330</ArticleId><ArticleId IdType="pmc">PMC9546784</ArticleId><ArticleId IdType="pubmed">36220361</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee M., Pal R., Dutta S. Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis. Prim. Care Diabetes. 2022;16:591&#x2013;593. doi: 10.1016/j.pcd.2022.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2022.05.009</ArticleId><ArticleId IdType="pmc">PMC9148988</ArticleId><ArticleId IdType="pubmed">35654679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M., Rigatelli G., Bilato C., Pasquetto G., Mazza A. Risk of Incident New-Onset Arterial Hypertension after COVID-19 Recovery: A Systematic Review and Meta-analysis. High Blood Press. Cardiovasc. Prev. 2023;30:227&#x2013;233. doi: 10.1007/s40292-023-00574-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40292-023-00574-5</ArticleId><ArticleId IdType="pmc">PMC10105348</ArticleId><ArticleId IdType="pubmed">37060396</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E., Xie Y., Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: A cohort study. Lancet Diabetes Endocrinol. 2023;11:120&#x2013;128. doi: 10.1016/S2213-8587(22)00355-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00355-2</ArticleId><ArticleId IdType="pmc">PMC9873268</ArticleId><ArticleId IdType="pubmed">36623520</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz M.I., Saglam M., Caglar K., Cakir E., Sonmez A., Ozgurtas T., Aydin A., Eyileten T., Ozcan O., Acikel C., et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 2006;47:42&#x2013;50. doi: 10.1053/j.ajkd.2005.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2005.09.029</ArticleId><ArticleId IdType="pubmed">16377384</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang K.C., Imig J.D., Kalantar-Zadeh K., Gupta A. Kidney in the net of acute and long-haul coronavirus disease 2019: A potential role for lipid mediators in causing renal injury and fibrosis. Curr. Opin. Nephrol. Hypertens. 2022;31:36&#x2013;46. doi: 10.1097/MNH.0000000000000750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0000000000000750</ArticleId><ArticleId IdType="pubmed">34846312</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng L., Song X., Zhang M., Han Y., Chang G., Chang W., Shen Z. The pattern of cytokines expression and dynamic changes of renal function at 6 months in patients with Omicron COVID-19. J. Med. Virol. 2023;95:e28477. doi: 10.1002/jmv.28477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28477</ArticleId><ArticleId IdType="pubmed">36609778</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Z., Yuan S., Wei J., Xia S., Huang Y., Chen X., Han Y., Li Z., Xiao Y., Peng F., et al. Clinical and pathological features of omicron variant of SARS-CoV-2-associated kidney injury. J. Med. Virol. 2023;95:e29196. doi: 10.1002/jmv.29196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29196</ArticleId><ArticleId IdType="pubmed">37881096</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiquzzaman M., Thompson J.R., Shao S., Djurdjev O., Bevilacqua M., Wong M.M.Y., Levin A., Birks P.C. Long-term effect of COVID-19 infection on kidney function among COVID-19 patients followed in post-COVID-19 recovery clinics in British Columbia, Canada. Nephrol. Dial. Transplant. 2023;38:2816&#x2013;2825. doi: 10.1093/ndt/gfad121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfad121</ArticleId><ArticleId IdType="pubmed">37349962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam I.C.H., Wong C.K.H., Zhang R., Chui C.S.L., Lai F.T.T., Li X., Chan E.W.Y., Luo H., Zhang Q., Man K.K.C., et al. Long-term post-acute sequelae of COVID-19 infection: A retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60:102000. doi: 10.1016/j.eclinm.2023.102000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102000</ArticleId><ArticleId IdType="pmc">PMC10173760</ArticleId><ArticleId IdType="pubmed">37197226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H., Cao B. Severe COVID-19 and chronic kidney disease: Bidirectional mendelian randomization study. Virol. J. 2024;21:32. doi: 10.1186/s12985-023-02280-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02280-z</ArticleId><ArticleId IdType="pmc">PMC10823696</ArticleId><ArticleId IdType="pubmed">38287361</ArticleId></ArticleIdList></Reference><Reference><Citation>Taneska A.C., Rambabova-Bushljetik I., Markovska Z.S., Milenkova M., Vasileva A.S., Zafirova B., Pushevski V., Severova G., Trajceska L., Spasovski G. Predictive Admission Risk Factors, Clinical Features and Kidney Outcomes in COVID-19 Hospitalised Patients with Acute Kidney Injury. Prilozi. 2023;44:107&#x2013;119. doi: 10.2478/prilozi-2023-0054.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/prilozi-2023-0054</ArticleId><ArticleId IdType="pubmed">38109446</ArticleId></ArticleIdList></Reference><Reference><Citation>Babel N., Hugo C., Westhoff T.H. Vaccination in patients with kidney failure: Lessons from COVID-19. Nat. Rev. Nephrol. 2022;18:708&#x2013;723. doi: 10.1038/s41581-022-00617-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00617-5</ArticleId><ArticleId IdType="pmc">PMC9397175</ArticleId><ArticleId IdType="pubmed">35999285</ArticleId></ArticleIdList></Reference><Reference><Citation>Stai S., Lioulios G., Christodoulou M., Kasimatis E., Fylaktou A., Stangou M. COVID-19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation. Life. 2022;12:1358. doi: 10.3390/life12091358.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12091358</ArticleId><ArticleId IdType="pmc">PMC9505388</ArticleId><ArticleId IdType="pubmed">36143394</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai E.J., &#x10c;ih&#xe1;kov&#xe1; D., Tucker N.R. Cell-Specific Mechanisms in the Heart of COVID-19 Patients. Circ. Res. 2023;132:1290&#x2013;1301. doi: 10.1161/CIRCRESAHA.123.321876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.123.321876</ArticleId><ArticleId IdType="pmc">PMC10171292</ArticleId><ArticleId IdType="pubmed">37167361</ArticleId></ArticleIdList></Reference><Reference><Citation>Honchar O., Ashcheulova T. Short-term echocardiographic follow-up after hospitalization for COVID-19: A focus on early post-acute changes. Front. Cardiovasc. Med. 2023;10:1250656. doi: 10.3389/fcvm.2023.1250656.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1250656</ArticleId><ArticleId IdType="pmc">PMC10703357</ArticleId><ArticleId IdType="pubmed">38075959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M., Rigatelli G., Roncon L., Pasquetto G., Bilato C. Risk of incident heart failure after COVID-19 recovery: A systematic review and meta-analysis. Heart. Fail. Rev. 2023;28:859&#x2013;864. doi: 10.1007/s10741-022-10292-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-022-10292-0</ArticleId><ArticleId IdType="pmc">PMC9792307</ArticleId><ArticleId IdType="pubmed">36572763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy P.U., Udupa H., Ks J., Babu S.K.N., Jain N., Das R., Upadhyai P. The impact of COVID-19 on pulmonary, neurological, and cardiac outcomes: Evidence from a Mendelian randomization study. Front. Public Health. 2023;11:1303183. doi: 10.3389/fpubh.2023.1303183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1303183</ArticleId><ArticleId IdType="pmc">PMC10752946</ArticleId><ArticleId IdType="pubmed">38155884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M., Rigatelli G., Battisti V., Costola G., Roncon L., Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. Int. J. Cardiol. 2023;372:138&#x2013;143. doi: 10.1016/j.ijcard.2022.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2022.12.032</ArticleId><ArticleId IdType="pmc">PMC9755219</ArticleId><ArticleId IdType="pubmed">36535564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M., Mazzitelli M., Rigatelli G., Bilato C., Cattelan A.M. Risk of ischemic stroke in patients recovered from COVID-19 infection: A systematic review and meta-analysis. Eur. Stroke J. 2023;8:915&#x2013;922. doi: 10.1177/23969873231190432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23969873231190432</ArticleId><ArticleId IdType="pmc">PMC10372514</ArticleId><ArticleId IdType="pubmed">37491810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Ming X.F. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res. 2006;4:53&#x2013;65. doi: 10.3121/cmr.4.1.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.3121/cmr.4.1.53</ArticleId><ArticleId IdType="pmc">PMC1435659</ArticleId><ArticleId IdType="pubmed">16595793</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer V., Sotnikova R. Nitric oxide-the endothelium-derived relaxing factor and its role in endothelial functions. Gen. Physiol. Biophys. 2010;29:319&#x2013;340. doi: 10.4149/gpb_2010_04_319.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/gpb_2010_04_319</ArticleId><ArticleId IdType="pubmed">21156995</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankevicius E., Kevelaitis E., Vainorius E., Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina. 2003;39:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738901</ArticleId></ArticleIdList></Reference><Reference><Citation>Koushki K., Shahbaz S.K., Mashayekhi K., Sadeghi M., Zayeri Z.D., Taba M.Y., Banach M., Al-Rasadi K., Johnston T.P., Sahebkar A. Anti-inflammatory Action of Statins in Cardiovascular Disease: The Role of Inflammasome and Toll-Like Receptor Pathways. Clin. Rev. Allergy Immunol. 2021;60:175&#x2013;199. doi: 10.1007/s12016-020-08791-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-020-08791-9</ArticleId><ArticleId IdType="pmc">PMC7985098</ArticleId><ArticleId IdType="pubmed">32378144</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniades C., Bakogiannis C., Leeson P., Guzik T.J., Zhang M.H., Tousoulis D., Antonopoulos A.S., Demosthenous M., Marinou K., Hale A., et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335&#x2013;345. doi: 10.1161/CIRCULATIONAHA.110.985150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.985150</ArticleId><ArticleId IdType="pmc">PMC5357054</ArticleId><ArticleId IdType="pubmed">21730307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola S., Mir M.Q., Lerakis S., Tandon N., Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol. 2006;47:332&#x2013;337. doi: 10.1016/j.jacc.2005.06.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2005.06.088</ArticleId><ArticleId IdType="pubmed">16412856</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Zhang S., Jiang H., Sun A., Wang Y., Zou Y., Ge J., Chen H. Effects of statin therapy on inflammatory markers in chronic heart failure: A meta-analysis of randomized controlled trials. Arch. Med. Res. 2010;41:464&#x2013;471. doi: 10.1016/j.arcmed.2010.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2010.08.009</ArticleId><ArticleId IdType="pubmed">21044751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubari M.I.M. Effect of omega-3 fatty acid supplementation on markers of inflammation and endothelial function in patients with chronic heart disease: A systematic review and meta-analysis. Cell. Mol. Biol. 2024;70:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">38836663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015;373:2117&#x2013;2128. doi: 10.1056/NEJMoa1504720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504720</ArticleId><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N., Shaw W., Law G., Desai M., Matthews D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 2017;377:644&#x2013;657. doi: 10.1056/NEJMoa1611925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1611925</ArticleId><ArticleId IdType="pubmed">28605608</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H. Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes. Ann. Transl. Med. 2017;5:470. doi: 10.21037/atm.2017.09.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2017.09.22</ArticleId><ArticleId IdType="pmc">PMC5733321</ArticleId><ArticleId IdType="pubmed">29285503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., Silverman M.G., Zelniker T.A., Kuder J.F., Murphy S.A., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2019;380:347&#x2013;357. doi: 10.1056/NEJMoa1812389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1812389</ArticleId><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C., Inzucchi S.E., Lachin J.M., Fitchett D., von Eynatten M., Mattheus M., Johansen O.E., Woerle H.J., Broedl U.C., Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 2016;375:323&#x2013;334. doi: 10.1056/NEJMoa1515920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1515920</ArticleId><ArticleId IdType="pubmed">27299675</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019;380:2295&#x2013;2306. doi: 10.1056/NEJMoa1811744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1811744</ArticleId><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherney D.Z.I., Zinman B., Inzucchi S.E., Koitka-Weber A., Mattheus M., von Eynatten M., Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610&#x2013;621. doi: 10.1016/S2213-8587(17)30182-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(17)30182-1</ArticleId><ArticleId IdType="pubmed">28666775</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigiyama F., Kumashiro N., Miyagi M., Ikehara K., Kanda E., Uchino H., Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc. Diabetol. 2017;16:84. doi: 10.1186/s12933-017-0564-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-017-0564-0</ArticleId><ArticleId IdType="pmc">PMC5500953</ArticleId><ArticleId IdType="pubmed">28683796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A.J., Sanchez M.J., Sanchez R.A. Diabetic patients with essential hypertension treated with amlodipine: Blood pressure and arterial stiffness effects of canagliflozin or perindopril. J. Hypertens. 2019;37:636&#x2013;642. doi: 10.1097/HJH.0000000000001907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001907</ArticleId><ArticleId IdType="pubmed">30113526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sezai A., Sekino H., Unosawa S., Taoka M., Osaka S., Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc. Diabetol. 2019;18:76. doi: 10.1186/s12933-019-0877-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0877-2</ArticleId><ArticleId IdType="pmc">PMC6551875</ArticleId><ArticleId IdType="pubmed">31167663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozdnyakova D.D., Bakhareva T.A., Baranova I.A., Selemir V.D., Chuchalin A.G. Rehabilitation program of post-COVID-19 syndrome with the use of nitric oxide and molecular hydrogen. Ter. Arkh. 2024;96:260&#x2013;265. doi: 10.26442/00403660.2024.03.202639.</Citation><ArticleIdList><ArticleId IdType="doi">10.26442/00403660.2024.03.202639</ArticleId><ArticleId IdType="pubmed">38713041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Xie Y., Dong G., Yin M., Shang Z., Zhou K., Bao D., Zhou J. The Effect of 14-Day Consumption of Hydrogen-Rich Water Alleviates Fatigue but Does Not Ameliorate Dyspnea in Long-COVID Patients: A Pilot, Single-Blind, and Randomized, Controlled Trial. Nutrients. 2024;16:1529. doi: 10.3390/nu16101529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu16101529</ArticleId><ArticleId IdType="pmc">PMC11123997</ArticleId><ArticleId IdType="pubmed">38794767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G., Meininger C.J., McNeal C.J., Bazer F.W., Rhoads J.M. Role of l-Arginine in nitric oxide synthesis and health in humans. Adv. Exp. Med. Biol. 2021;1332:167&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">34251644</ArticleId></ArticleIdList></Reference><Reference><Citation>Adebayo A., Varzideh F., Wilson S., Gambardella J., Eacobacci M., Jankauskas S.S., Donkor K., Kansakar U., Trimarco V., Mone P., et al. l-Arginine and COVID-19: An Update. Nutrients. 2021;13:3951. doi: 10.3390/nu13113951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13113951</ArticleId><ArticleId IdType="pmc">PMC8619186</ArticleId><ArticleId IdType="pubmed">34836206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 2005;5:641&#x2013;654. doi: 10.1038/nri1668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1668</ArticleId><ArticleId IdType="pubmed">16056256</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli M.B., Gambardella J., Castellanos V., Trimarco V., Santulli G. Vitamin C and Cardiovascular Disease: An Update. Antioxidants. 2020;9:1227. doi: 10.3390/antiox9121227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9121227</ArticleId><ArticleId IdType="pmc">PMC7761826</ArticleId><ArticleId IdType="pubmed">33287462</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller R., Munscher-Paulig F., Grabner R., Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J. Biol. Chem. 1999;274:8254&#x2013;8260. doi: 10.1074/jbc.274.12.8254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.12.8254</ArticleId><ArticleId IdType="pubmed">10075731</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A., Vita J.A., Venema R.C., Keaney J.F., Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J. Biol. Chem. 2000;275:17399&#x2013;17406. doi: 10.1074/jbc.M002248200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M002248200</ArticleId><ArticleId IdType="pubmed">10749876</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker T.A., Milstien S., Katusic Z.S. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J. Cardiovasc. Pharmacol. 2001;37:333&#x2013;338. doi: 10.1097/00005344-200103000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005344-200103000-00012</ArticleId><ArticleId IdType="pubmed">11243424</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvani R., Gervasoni J., Picca A., Ciciarello F., Galluzzo V., Coelho-J&#xfa;nior H.J., Di Mario C., Gremese E., Lomuscio S., Paglionico A.M., et al. Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial. Int. J. Mol. Sci. 2023;24:5078. doi: 10.3390/ijms24065078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065078</ArticleId><ArticleId IdType="pmc">PMC10049539</ArticleId><ArticleId IdType="pubmed">36982151</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo R., Trimarco V., Mone P., Alo&#xe8; T., Capra Marzani M., Diana A., Fazio G., Mallardo M., Maniscalco M., Marazzi G., et al. Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey. Pharmacol. Res. 2022;183:106360. doi: 10.1016/j.phrs.2022.106360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106360</ArticleId><ArticleId IdType="pmc">PMC9295384</ArticleId><ArticleId IdType="pubmed">35868478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M., Calvanim R., Picca A., Ciciarello F., Galluzzo V., Coelho-J&#xfa;nior H.J., Di Giorgio A., Di Mario C., Gervasoni J., Gremese E., et al. Effects of l-Arginine Plus Vitamin C Supplementation on Physical Performance, Endothelial Function, and Persistent Fatigue in Adults with Long COVID: A Single-Blind Randomized Controlled Trial. Nutrients. 2022;14:4984. doi: 10.3390/nu14234984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14234984</ArticleId><ArticleId IdType="pmc">PMC9738241</ArticleId><ArticleId IdType="pubmed">36501014</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta M.A., Marino G., Spagnolo B., Bianchi F.P., Falappone P.C.F., Spagnolo L., Gatti P. Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome. Clin. Exp. Med. 2023;23:667&#x2013;678. doi: 10.1007/s10238-022-00871-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-022-00871-8</ArticleId><ArticleId IdType="pmc">PMC9395797</ArticleId><ArticleId IdType="pubmed">35994177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghdoust M., Aligolighasemabadi F., Dehesh T., Taefehshokr N., Sadeghdoust A., Kotfis K., Hashemiattar A., Ravandi A., Aligolighasemabadi N., Vakili O., et al. The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study. Arch. Immunol. Ther. Exp. 2023;71:8. doi: 10.1007/s00005-023-00672-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-023-00672-1</ArticleId><ArticleId IdType="pmc">PMC9972324</ArticleId><ArticleId IdType="pubmed">36853269</ArticleId></ArticleIdList></Reference><Reference><Citation>Grote K., Schaefer A.C., Soufi M., Ruppert V., Linne U., Mukund Bhagwat A., Szymanski W., Graumann J., Gercke Y., Aldudak S., et al. Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2. Int. J. Mol. Sci. 2024;25:4522. doi: 10.3390/ijms25084522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25084522</ArticleId><ArticleId IdType="pmc">PMC11049911</ArticleId><ArticleId IdType="pubmed">38674105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.P., Chang C.M., Yang C.C., Pariante C.M., Su K.P. Long COVID and long chain fatty acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain. Behav. Immun. 2022;103:19&#x2013;27. doi: 10.1016/j.bbi.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC8977215</ArticleId><ArticleId IdType="pubmed">35390469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mroueh A., Fakih W., Carmona A., Trimaille A., Matsushita K., Marchandot B., Qureshi A.W., Gong D.S., Auger C., Sattler L., et al. COVID-19 promotes endothelial dysfunction and thrombogenicity: Role of proinflammatory cytokines/SGLT2 prooxidant pathway. J. Thromb. Haemost. 2024;22:286&#x2013;299. doi: 10.1016/j.jtha.2023.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.09.022</ArticleId><ArticleId IdType="pubmed">37797691</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R., Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J. Clin. Cases. 2020;8:3621&#x2013;3644. doi: 10.12998/wjcc.v8.i17.3621.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v8.i17.3621</ArticleId><ArticleId IdType="pmc">PMC7479552</ArticleId><ArticleId IdType="pubmed">32953841</ArticleId></ArticleIdList></Reference><Reference><Citation>Koz&#x142;owski P., Leszczy&#x144;ska A., Ciepiela O. Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review. Am. J. Med. Open. 2024;11:100068. doi: 10.1016/j.ajmo.2024.100068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajmo.2024.100068</ArticleId><ArticleId IdType="pmc">PMC11256271</ArticleId><ArticleId IdType="pubmed">39034937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>